Comparison of Tolerability Between Two Allergy Drops

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT01390961
• Date of registration: 07/07/2011
• Primary sponsor: Hom, Milton M., OD, FAAO
• Public title: Comparison of Tolerability Between Two Allergy Drops
• Scientific title: Comparison of Tolerability Between Two Allergy Drops
• Date of first enrolment: August 2011
• Target sample size: 48
• Recruitment status: Enrolling by invitation
• URL: http://clinicaltrials.gov/show/NCT01390961
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Countries of recruitment

United States

Key inclusion & exclusion criteria

Inclusion Criteria:

- Between the ages of 18 and over inclusive.

- Males or females

- Patient is in generally good & stable overall health.

- Patient likely to comply with study guidelines & study visits.

- Informed consent signed.

- History of allergic conjunctivitis

- Current symptoms of allergic conjunctivitis assessed by the investigator

Exclusion Criteria:

- Corneal refractive surgery or contact lens wear within 6 months of this study.

- Current use of Restasis

- Intra-ocular surgery within 6 months or ocular laser surgery within 6 months.

- Pregnant or lactating women.

- Ocular pathology (includes glaucoma and cataract), which could impact results and/or
place patient at risk.



Age minimum: 18 Months
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Allergic Conjunctivitis

Intervention(s)

Drug: alacaftadine and naphazoline HCl & pheniramine maleate

Primary Outcome(s)

Tolerability [Time Frame: 8 weeks]

Secondary ID(s)

IIT-000256

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Allergan